Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy Development
Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Hold rating on Fate Therapeutics (FATE – Research Report). The ...
bovnews2d
Fate Therapeutics Inc (FATE) Stock Rated Neutral by BofA Securities
Fate Therapeutics Inc (FATE) stock saw a decline, ending the day at $1.83 which represents a decrease of $-0.09 or -4.69% from the prior close of $1.92. The stock opened at $1.97 and touched a low of ...
Barclays Gives a Buy Rating to Fate Therapeutics (FATE)
In a report released today, Peter Lawson from Barclays assigned a Buy rating to Fate Therapeutics (FATE – Research Report), with a price target ...
Lupus Foundation of America4d
Fate Therapeutics Announces Promising Initial Data from FT819 Phase 1 Study for Moderate to Severe Systemic Lupus Erythematosus
Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with ...
Nasdaq4d
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Fate Therapeutics (FATE). Shares have added about 0.5% in that time frame, underperforming the S&P 500. Will the recent positive trend ...
bovnews6d
Why Did Fate Therapeutics Inc (FATE) Stock See -28.80% Plunge in the Last 90 Days?
On Monday, Fate Therapeutics Inc (FATE) stock saw a modest uptick, ending the day at $2.72 which represents a slight increase of $0.07 or 2.64% from the prior close of $2.65. The stock opened at $ and ...
Morningstar5d
Fate Therapeutics Inc FATE
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...